Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
J Biochem Mol Toxicol ; 37(12): e23493, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37661808

ABSTRACT

Long noncoding RNA (lncRNA) prostate cancer-associated transcript 29 (PCAT29) is known to suppress several cancers, but its participation in hepatocellular carcinoma (HCC) remains elusive. This study tried to explore PCAT29 function in HCC. In this study, a total of 62 HCC patients were enrolled. Tissue samples were collected from all 62 patients to isolate RNA samples. Quantitative reverse transcription polymerase chain reaction was applied for the expression analysis of PCAT29 and microRNA-155 (miR-155) in these tissue samples. The 62 HCC patients were followed up for 5 years to explore the prognostic value of PCAT29 for HCC. Correlations were analyzed using linear regression. IntaRNA 2.0 was used to predict the interaction between PCAT29 and miR-155. The role of PCAT29 and miR-155 in regulating HCC cell invasion and migration was evaluated by Transwell assay. We found that PCAT29 expression was downregulated in HCC and miR-155 expression was upregulated in HCC compared to nontumor samples (p < 0.001). Downregulation of PCAT29 was found to be closely associated with poor survival of HCC patients. MiR-155 was inversely correlated with PCAT29. It was predicted that miR-155 could target PCAT29. In HCC cells, miR-155 overexpression resulted in reduced PCAT29 expression (p < 0.05). MiR-155 counteracted the inhibitory effects of PCAT29 overexpression on HCC cell migration and invasion. These results suggest that PCAT29 may be a potential prognostic biomarker and a novel therapeutic target for treating HCC.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , MicroRNAs , Prostatic Neoplasms , RNA, Long Noncoding , Male , Humans , Carcinoma, Hepatocellular/metabolism , RNA, Long Noncoding/genetics , RNA, Long Noncoding/metabolism , Liver Neoplasms/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , Cell Line, Tumor , Cell Movement/genetics , Gene Expression Regulation, Neoplastic , Prostatic Neoplasms/genetics , Neoplasm Invasiveness/genetics , Cell Proliferation/genetics
2.
Genet Med ; 24(1): 157-169, 2022 01.
Article in English | MEDLINE | ID: mdl-34906508

ABSTRACT

PURPOSE: More than half of the familial cutaneous melanomas have unknown genetic predisposition. This study aims at characterizing a novel melanoma susceptibility gene. METHODS: We performed exome and targeted sequencing in melanoma-prone families without any known melanoma susceptibility genes. We analyzed the expression of candidate gene DENND5A in melanoma samples in relation to pigmentation and UV signature. Functional studies were carried out using microscopic approaches and zebrafish model. RESULTS: We identified a novel DENND5A truncating variant that segregated with melanoma in a Swedish family and 2 additional rare DENND5A variants, 1 of which segregated with the disease in an American family. We found that DENND5A is significantly enriched in pigmented melanoma tissue. Our functional studies show that loss of DENND5A function leads to decrease in melanin content in vitro and pigmentation defects in vivo. Mechanistically, harboring the truncating variant or being suppressed leads to DENND5A losing its interaction with SNX1 and its ability to transport the SNX1-associated vesicles from melanosomes. Consequently, untethered SNX1-premelanosome protein and redundant tyrosinase are redirected to lysosomal degradation by default, causing decrease in melanin content. CONCLUSION: Our findings provide evidence of a physiological role of DENND5A in the skin context and link its variants to melanoma susceptibility.


Subject(s)
Guanine Nucleotide Exchange Factors/genetics , Melanoma , Skin Neoplasms , Animals , Genetic Predisposition to Disease , Humans , Melanoma/genetics , Melanosomes , Monophenol Monooxygenase/metabolism , Skin Neoplasms/genetics , Sorting Nexins , Exome Sequencing , Zebrafish/genetics
3.
J Environ Manage ; 324: 116324, 2022 Dec 15.
Article in English | MEDLINE | ID: mdl-36179478

ABSTRACT

To achieve sustainable development, local governments are under enormous pressure to simultaneously achieve the three assessment tasks (TATs) of energy saving, CO2 reduction, and pollution reduction. However, the TATs are often managed by different authorities and have three types of measures (TTMs) that correspond to them. The lack of adequate cooperation between these authorities has led to the inefficient investment of policy resources and even to policy conflicts, and the interactions among the TTMs are not yet known. To this end, this paper uses the MCEE model to assess the interactions among the TTMs quantitatively using Guangzhou, China, as a case study. The results showed the following. (1) According to the current development trend, if the authorities managing the TATs continue to work alone, they will not be able to fulfill the corresponding assessment tasks in the future. (2) The TTMs have interactions with each other, and their synergies are far greater than their trade-offs. From 2015 to 2035, it is expected that energy-saving measures can accomplish 54.39% of the CO2 reduction tasks and 32.74% of the pollution reduction tasks indirectly, and low-carbon measures can accomplish 55.53% of the energy saving tasks and 27.20% of the pollution reduction tasks indirectly, However, environmental-protection measures will cause fewer trade-offs (energy demand and CO2 emissions increase by 3.76% and 2.88%, respectively). (3) In some years, the contribution of interactions among the TTMs are even higher than their direct contribution to the TATs. Our findings suggest that intensive cooperation between authorities is necessary, and that the benefits of such cooperation will outweigh the disadvantages.


Subject(s)
Ecosystem , Sustainable Development , Urban Renewal , Carbon Dioxide , China
4.
Nanotechnology ; 31(31): 315302, 2020 Jul 31.
Article in English | MEDLINE | ID: mdl-32303011

ABSTRACT

A double-sided nanoimprint lithography metal transfer method has been developed to fabricate a flexible capacitive touch sensor. The electrodes of this sensor are aligned and overlapped to each other and consist of a diamond aluminum mesh, which achieved a transmittance of 94% and anisotropic surface resistivity. The maximum capacitance change of the touch sensor unit is up to 41.8% when fullly touched. A 3 × 3 sensor array was tested to prove good touch detection function and the potential for large-scale applications.

5.
Med Sci Monit ; 26: e922149, 2020 Apr 14.
Article in English | MEDLINE | ID: mdl-32284524

ABSTRACT

BACKGROUND Leonurine is an active component of the traditional Chinese medicine Leonurus japonicus. This study aimed to investigate the effects of overexpressed CYP450s on the metabolic activity of leonurine. MATERIAL AND METHODS BEAS-2B cells stably expressing CYP1A1, 1A2, 2A13, 2B6, and 3A4 were constructed. CYP450s expression was identified using reverse-transcription PCR and Western blot assay. CCK-8 assay was used to evaluate the effect of leonurine on cell activity. Leonurine was incubated in vitro with CYP1A1, 1A2, 2A13, 2B6, and 3A4 metabolic enzymes to evaluate the clearance rate of CYP450 enzymes for leonurine. UPLC-MS was used to detect changes of drug concentration and discover the main metabolic enzymes affecting leonurine. RESULTS BEAS-2B cells stably expressing CYP1A1, 1A2, 2A13, 2B6, and 3A4 were successfully constructed. According to primary mass spectra and secondary mass spectra of leonurine, the main metabolic enzymes were 312.1550 [H+] and 181.0484. Compared to the control group, residue of leonurine in CYP2A13 group was significantly reduced (F=5.307, p=0.024). Compared to the 0-min group, the clearance rate of leonurine in the CYP2A13-treated group was significantly decreased at 120 min after treatment (F=7.273, p=0.007). CCK-8 results also showed that activity of BEAS-2B cells that overexpress CYP2A13 gradually decreased with increased concentration of leonurine. Although CYP2A13 demonstrated good metabolic activity for leonurine, we found that CYP1A1, 1A2, 2B6, and 3A4 had no metabolic effects on leonurine. CONCLUSIONS Leonurine can be effectively activated through CYP2A13 enzyme metabolism, and further inhibits activity of human lung epithelial cells (BEAS-2B). Therefore, CYP2A13 is a main metabolic enzyme for leonurine in BEAS-2B cells.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Epithelial Cells/drug effects , Epithelial Cells/enzymology , Gallic Acid/analogs & derivatives , Bronchi/cytology , Cell Line , Gallic Acid/pharmacology , Humans , Inactivation, Metabolic
6.
Nanotechnology ; 30(7): 075301, 2019 Feb 15.
Article in English | MEDLINE | ID: mdl-30524012

ABSTRACT

A plate-to-roll nanoimprint lithography (P2RNIL) system has been developed to realize a high-speed, large-scale and high-resolution nanoimprint process. Imprinted patterns have been achieved with a linewidth of less than 75 nm at a speed of 22 cm2 s-1 on flexible substrate. To improve the quality of the imprinted patterns, we have proposed a compliant mechanism which can realize passive alignment and minimize the lateral displacement between template and substrate. Finite element analysis of this compliant mechanism was carried out. By using the P2RNIL system, wire-grid polarizers (up to a 10 030:1 extinction ratio and up to 88% transmittance) and transparent metal electrodes whose performance is in good accordance with simulated results were successfully fabricated.

8.
Genes Chromosomes Cancer ; 55(7): 601-11, 2016 07.
Article in English | MEDLINE | ID: mdl-27074266

ABSTRACT

We applied a targeted sequencing approach to identify germline mutations conferring a moderately to highly increased risk of cutaneous and uveal melanoma. Ninety-two high-risk melanoma patients were screened for inherited variation in 120 melanoma candidate genes. Observed gene variants were filtered based on frequency in reference populations, cosegregation with melanoma in families and predicted functional effect. Several novel or rare genetic variants in genes involved in DNA damage response, cell-cycle regulation and transcriptional control were identified in melanoma patients. Among identified genetic alterations was an extremely rare variant (minor allele frequency of 0.00008) in the BRIP1 gene that was found to cosegregate with the melanoma phenotype. We also found a rare nonsense variant in the BRCA2 gene (rs11571833), previously associated with cancer susceptibility but not with melanoma, which showed weak association with melanoma susceptibility in the Swedish population. Our results add to the growing knowledge about genetic factors associated with melanoma susceptibility and also emphasize the role of DNA damage response as an important factor in melanoma etiology. © 2016 Wiley Periodicals, Inc.


Subject(s)
BRCA2 Protein/genetics , DNA Damage/genetics , DNA-Binding Proteins/genetics , Genetic Predisposition to Disease , Germ-Line Mutation/genetics , Melanoma/genetics , RNA Helicases/genetics , Adult , Aged , Aged, 80 and over , Case-Control Studies , DNA, Neoplasm/analysis , DNA, Neoplasm/genetics , Fanconi Anemia Complementation Group Proteins , Female , Follow-Up Studies , Humans , Male , Melanoma/pathology , Middle Aged , Pedigree , Prognosis
9.
Prostate ; 75(13): 1363-75, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26015225

ABSTRACT

BACKGROUND: The sex determing region Y-box 4 (SOX4) gene is a critical developmental transcriptional factor that is overexpressed in prostate cancer (PCa). While we and others have investigated the role of SOX4 overexpression in PCa, the molecular mechanism underlying its aberrant expression remains unclear. METHODS: Immunohistochemistry were utilized to detect SOX4 expression and the correlation between estrogen receptor ß (ERß), androgen receptor (AR) and SOX4 in a cohort of 94 clinical specimens. Real-time quantitative PCR and Western blotting were used to study the transcript and protein expression levels. Immunofluorescence staining and co-immunoprecipitation were performed to assess the interaction and subcellular location of ERß and AR. Chromatin immunoprecipitation (ChIP) assays and Luciferase reporter assays were performed to explore the binding and transcriptional activities of ERß and AR to the SOX4 promoter. Cellular function was evaluated by MTS, invasion and wound healing assays. RESULTS: SOX4 expression is up-regulated in Castration-Resistant Prostate Cancer (CRPC) tumors compared to hormone-dependent PCa (HDPC) cases. Increased expression was also observed in PCa cells after long-term androgen-deprivation treatment (ADT). In vitro data indicated that SOX4 is an AR transcriptional target and down-regulated by dihydrotestosterone (DHT) via AR. 17ß-estradiol (E2) up-regulates SOX4 expression in the absence of androgen through the formation of a protein complex between ERß and AR. Knockdown of AR or ERß blocks the E2-induced SOX4 expression. ChIP assays confirmed that both ERß and AR bind to the SOX4 promoter in response to E2. Functionally, silencing SOX4 significantly attenuates the proliferative effect, as well as the capacity of migration and invasion of E2 on PCa cells. Clinically, overexpression of SOX4 is significantly associated with ERß expression in PCa. In addition, this association is still retained in CRPC patients with poor prognosis. CONCLUSION: These findings suggest that SOX4 is a novel DHT-repressed AR-target gene. E2 could promote proliferation of PCa cells through the up-regulation of SOX4 under androgen-depleted environment. Our data provides a possible molecular basis for the overexpression of SOX4 in CRPC and may facilitate the detection and prevention of the emergence of CRPC.


Subject(s)
Estradiol/pharmacology , Prostate/metabolism , Prostatic Neoplasms/metabolism , SOXC Transcription Factors/metabolism , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , Disease Progression , Estrogen Receptor beta/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Humans , Male , Neoplasm Invasiveness/pathology , Prostate/drug effects , Prostate/pathology , Prostatic Neoplasms/pathology , Receptors, Androgen/metabolism , Up-Regulation/drug effects
10.
Drug Dev Res ; 76(7): 368-74, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26310899

ABSTRACT

Preclinical Research Breast cancer is the most prevalent malignancy in women with more than 1.3 million new cases every year worldwide. Chemotherapy is a critical therapeutic strategy for breast cancer, while chemoresistance remains a major obstacle to treatment success. In the past two decades, significant progress has been achieved in understanding drug resistance in breast cancer, involving drug efflux, alterations in DNA repair pathways, suppression of apoptosis as well as epithelial-mesenchymal transition, and cancer stem cells. However, more effective therapeutic targets and novel biomarkers are still urgently needed to improve the overall survival and refine the therapeutic strategy for breast cancer patients. MicroRNAs (miRNAs) play crucial roles in cellular processes, such as cell differentiation, proliferation, and apoptosis. The recent discovery of miRNAs in malignancy has provided new directions for research on mechanisms underlying response to chemotherapy. Furthermore, several studies have documented that selected miRNAs, such as miR-200c and miR-34a, may influence response to chemotherapy in several tumor types, including breast cancer. The use of miRNAs as therapeutic targets to overcome chemoresistance is currently under investigation. In this review, we summarize the roles of miRNAs in chemoresistance through multiple molecular mechanisms, and highlight the potential diagnostic and therapeutic applications of miRNAs in overcoming breast cancer chemoresistance.


Subject(s)
Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/genetics , MicroRNAs/genetics , Female , Gene Expression Regulation, Neoplastic/genetics , Humans , MicroRNAs/drug effects , Molecular Targeted Therapy
11.
Prostate ; 74(6): 647-58, 2014 May.
Article in English | MEDLINE | ID: mdl-24435928

ABSTRACT

BACKGROUND: Approximately 50% of prostate cancer (PCa) patients in Western countries harbor ERG rearrangement with concurrent ERG overexpression. Overexpression of SOX4 has been shown to play important roles in multiple cancers including PCa. However, the link between these two critical genetic aberrations was unclear. METHODS: Fluorescence in situ hybridization and immunohistochemistry were utilized to detect ERG rearrangement and SOX4 expression. Cellular function was evaluated by transwell, wound healing assays, and cell adhesion assay, respectively. Interaction between ERG and SOX4 was arrayed by co-immunoprecipitation, Real-time PCR, Western blot, and siRNA. Direct binding of ERG to the promoter of SOX4, as well as epigenetic modifications of their promoters after TGF-ß1 treatment was monitored by chromatin immunoprecipitation. RESULTS: ERG regulated SOX4 expression via binding to its promoter. Silencing both of them showed duplicate effects on restoring the epithelial characteristics, increasing cellular adhesion and decreasing capacity of cellular migration and invasion. ERG and SOX4 have cooperative roles in TGF-ß1-induced epithelial to mesenchymal transition (EMT) process. In addition, TGF-ß1 stimulation increased levels of chromatin marks associated with active genes (H3K4me3, H416ac), and decreased levels of repressive marks (H3K27me3) at their promoters. 5-aza and TSA treatment changed expressions of ERG and SOX4. Clinically, overexpression of SOX4 is associated with ERG rearrangement status in PCa and ERG+/SOX4+ defined a subset of PCa patients with poor prognosis. CONCLUSION: Our findings define a key role for ERG/SOX4 in the development of a subset of PCa and highlight the clinical importance of identifying molecularly defined tumor subgroups.


Subject(s)
Epithelial-Mesenchymal Transition/physiology , Prostate/metabolism , Prostatic Neoplasms/metabolism , SOXC Transcription Factors/metabolism , Trans-Activators/metabolism , Adult , Cell Adhesion/drug effects , Cell Adhesion/physiology , Cell Line, Tumor , Cell Movement/drug effects , Cell Movement/physiology , Epithelial-Mesenchymal Transition/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/physiology , Humans , Male , Promoter Regions, Genetic , Prostate/drug effects , Prostate/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , SOXC Transcription Factors/genetics , Trans-Activators/genetics , Transcriptional Regulator ERG , Transforming Growth Factor beta1/pharmacology
12.
Biochem Biophys Res Commun ; 452(3): 614-21, 2014 Sep 26.
Article in English | MEDLINE | ID: mdl-25181339

ABSTRACT

Overexpressions of EGFR and HER2 are thought to be prognostic factors of cholangiocarcinoma (CCA). The SOX4 transcription factor is involved in the development and cell fate decision. Although up-regulation of SOX4 has been described in multiple human malignancies, the prognostic value of SOX4 and its relationship to EGFR/HER2 in CCA remain unclear. In the current study, we showed that SOX4 and EGFR were overexpressed in 17 (29.3%), and 13 (22.4%) of the 58 intrahepatic cholangiocarcinomas (IHCCs), as well as 28 (29.8%), and 33 (35.1%) of the 94 extrahepatic cholangiocarcinomas (EHCCs), respectively. Overexpression of HER2 was exclusively identified in EHCCs, with the rate being 4.4% (4/90). In all, amplification of EGFR was identified in 1.8% (1/52) of IHCC cases, and in 2% (3/82) of EHCC cases. By contrast, HER2 amplification was present only in 3.5% (3/94) of the EHCC cases. Notably, Kaplan-Meier survival analysis suggested that SOX4 expression is a significant prognostic factor for poor prognosis in IHCC patients. Importantly, our findings suggested significant association of SOX4 and EGFR expression both in IHCC (P<0.001) and EHCC (P=0.014). SOX4 may modulate expression of EGFR, and SOX4+/EGFR+ defines a subset of CCA patients with poor prognosis. Finally, in vitro data indicated that SOX4 inhibits cellular migratory capacity and promotes epithelial-mesenchymal transition (EMT) process of CCA cells. Collectively, our results define an important role for SOX4 in CCA by orchestrating EMT and modulation on EGFR expression. SOX4 expression may serve as a prognostic marker for patients with IHCC.


Subject(s)
Bile Duct Neoplasms/genetics , Cholangiocarcinoma/genetics , ErbB Receptors/genetics , Gene Expression Regulation, Neoplastic , SOXC Transcription Factors/genetics , Aged , Bile Duct Neoplasms/diagnosis , Bile Duct Neoplasms/mortality , Bile Duct Neoplasms/pathology , Bile Ducts, Extrahepatic/metabolism , Bile Ducts, Extrahepatic/pathology , Bile Ducts, Intrahepatic/metabolism , Bile Ducts, Intrahepatic/pathology , Cell Line, Tumor , Cell Movement , Cholangiocarcinoma/diagnosis , Cholangiocarcinoma/mortality , Cholangiocarcinoma/pathology , Epithelial-Mesenchymal Transition , ErbB Receptors/metabolism , Female , Humans , Male , Middle Aged , Prognosis , Receptor, ErbB-2/genetics , Receptor, ErbB-2/metabolism , SOXC Transcription Factors/metabolism , Survival Analysis
13.
Biochem Biophys Res Commun ; 452(3): 746-52, 2014 Sep 26.
Article in English | MEDLINE | ID: mdl-25201727

ABSTRACT

Tumor metastasis is the leading cause of mortality and morbidity of prostate cancer (PCa) patients. Epithelial-mesenchymal transition (EMT) plays a critical role in cancer progression and metastasis. Recent evidence suggested that diabetic patients treated with metformin have lower PCa risk and better prognosis. This study was aimed to investigate the effects of metformin on EMT in PCa cells and the possible microRNA (miRNA)-based mechanisms. MiRNAs have been shown to regulate various processes of cancer metastasis. We herein showed that metformin significantly inhibits proliferation of Vcap and PC-3 cells, induces G0/G1 cell cycle arrest and inhibits invasiveness and motility capacity of Vcap cells. Metformin could inhibit TGF-ß-induced EMT in Vcap cells, as manifested by inhibition of the increase of N-cadherin (p=0.013), Vimentin (p=0.002) and the decrease of E-cadherin (p=0.0023) and ß-catenin (p=0.034) at mRNA and protein levels. Notably, we demonstrated significant upregulation of miR30a levels by metformin (P<0.05) and further experiments indicated that miR30a significantly inhibits proliferation and EMT process of Vcap cells. Interestingly, we identified that SOX4, a previously reported oncogenic transcriptional factor and modulator of EMT, is a direct target gene of miR30a. Finally, we screened the expression of miR30a and SOX4 in 84 PCa cases with radical prostatectomy. Of note, SOX4 overexpression is significantly associated with decreased levels of miR30a in PCa cases. In all, our study suggested that inhibition of EMT by metformin in PCa cells may involve upregulation of miR30a and downregulation of SOX4.


Subject(s)
Epithelial-Mesenchymal Transition/drug effects , Gene Expression Regulation, Neoplastic , Hypoglycemic Agents/pharmacology , Metformin/pharmacology , MicroRNAs/genetics , Prostatic Neoplasms/genetics , SOXC Transcription Factors/genetics , Antigens, CD/genetics , Antigens, CD/metabolism , Cadherins/genetics , Cadherins/metabolism , Cell Line, Tumor , Cell Movement/drug effects , G1 Phase Cell Cycle Checkpoints/drug effects , G1 Phase Cell Cycle Checkpoints/genetics , Genes, Reporter , Humans , Luciferases/genetics , Luciferases/metabolism , Male , MicroRNAs/metabolism , Prostate/metabolism , Prostate/pathology , Prostatectomy , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , SOXC Transcription Factors/metabolism , Signal Transduction , Transforming Growth Factor beta/pharmacology , beta Catenin/genetics , beta Catenin/metabolism
14.
iScience ; 27(2): 108832, 2024 Feb 16.
Article in English | MEDLINE | ID: mdl-38322993

ABSTRACT

Food plays a vital role in human sustenance and well-being, and the fluctuations in its price exert a significant impact on the attainment of the Sustainable Development Goals (SDGs) from social, economic, and environmental perspectives. This paper conducts an analysis utilizing data from 163 countries, revealing that an upsurge in global food commodity prices entails trade-offs with 13 SDGs, while exhibiting synergies with a few others. By considering specific food products, various types of countries, and the supply and demand shocks, further analysis confirms predominantly negative associations between spikes in food prices and the SDGs. Our findings highlight the urgent imperative to mitigate abrupt increases in food prices, such as those witnessed during the 2022 food crisis, to ensure the comprehensive fulfillment of the 2030 agenda for SDGs.

15.
Hepatol Int ; 2024 May 13.
Article in English | MEDLINE | ID: mdl-38740699

ABSTRACT

BACKGROUND: Evidence concerning long-term outcome of robotic liver resection (RLR) and laparoscopic liver resection (LLR) for hepatocellular carcinoma (HCC) patients is scarce. METHODS: This study enrolled all patients who underwent RLR and LLR for resectable HCC between July 2016 and July 2021. Propensity score matching (PSM) was employed to create a 1:3 match between the RLR and LLR groups. A comprehensive collection and analysis of patient data regarding efficacy and safety have been conducted, along with the evaluation of the learning curve for RLR. RESULTS: Following PSM, a total of 341 patients were included, with 97 in the RLR group and 244 in the LLR group. RLR group demonstrated a significantly longer operative time (median [IQR], 210 [152.0-298.0] min vs. 183.5 [132.3-263.5] min; p = 0.04), with no significant differences in other perioperative and short-term postoperative outcomes. Overall survival (OS) was similar between the two groups (p = 0.43), but RLR group exhibited improved recurrence-free survival (RFS) (median of 65 months vs. 56 months, p = 0.006). The estimated 5-year OS for RLR and LLR were 74.8% (95% CI: 65.4-85.6%) and 80.7% (95% CI: 74.0-88.1%), respectively. The estimated 5-year RFS for RLR and LLR were 58.6% (95% CI: 48.6-70.6%) and 38.3% (95% CI: 26.4-55.9%), respectively. In the multivariate Cox regression analysis, RLR (HR: 0.586, 95% CI (0.393-0.874), p = 0.008) emerged as an independent predictor of reducing recurrence rates and enhanced RFS. The operative learning curve indicates that approximately after the 11th case, the learning curve of RLR stabilized and entered a proficient phase. CONCLUSIONS: OS was comparable between RLR and LLR, and while RFS was improved in the RLR group. RLR demonstrates oncological effectiveness and safety for resectable HCC.

16.
Eur J Med Res ; 28(1): 324, 2023 Sep 07.
Article in English | MEDLINE | ID: mdl-37679821

ABSTRACT

BACKGROUND: Inflammatory disorders of the breast (IDB) damages the interests of women and children and hinders the progress of global health seriously. Several studies had offered clues between gut microbiota (GM) and inflammatory disorders of the breast (IDB). The gut-mammary gland axis also implied a possible contribution of the GM to IDB. However, the causality between them is still elusive. METHODS: The data of two-sample Mendelian randomization (MR) study related to the composition of GM (n = 18,340) and IDB (n = 177,446) were accessed from openly available genome-wide association studies (GWAS) database. As the major analytical method, inverse variance weighted (IVW) was introduced and several sensitive analytical methods were conducted to verify results. RESULTS: Inverse variance weighted revealed Eubacterium rectale group (OR = 1.87, 95% CI: 1.02-3.43, p = 4.20E-02), Olsenella (OR = 1.29, 95% CI: 1.02-1.64, p = 3.30E-02), Ruminiclostridium-6 (OR = 1.53, 95% CI: 1.08-2.14, p = 1.60E-02) had an anti-protective effect on IDB. Peptococcus (OR = 0.75, 95% CI: 0.60-0.94, p = 1.30E-02) had a protective effect on IDB. The results were credible through a series of test. CONCLUSIONS: We revealed causality between IDB and GM taxa, exactly including Ruminiclostridium-6, Eubacterium rectale group, Olsenella and Peptococcus. These genera may become novel biomarkers and supply new viewpoint for probiotic treatment. However, these findings warrant further test owing to the insufficient evidences.


Subject(s)
Actinobacteria , Gastrointestinal Microbiome , Probiotics , Child , Female , Humans , Gastrointestinal Microbiome/genetics , Genome-Wide Association Study , Evidence Gaps
17.
J Clin Med ; 12(6)2023 Mar 10.
Article in English | MEDLINE | ID: mdl-36983169

ABSTRACT

BACKGROUND: Short-term outcomes of laparoscopic hepatectomy of central-located liver lesions (LHCL) compared with traditional open hepatectomy of central-located liver lesions (OHCL) remain unclear. The aim of this study was to explore the safety and efficacy of LHCL. METHODS: A retrospective analysis was performed on 262 patients who underwent hepatectomies involving resections of liver segment II, IV or VIII from January 2015 to June 2021 in two institutions. Patients in the LHCL group were matched in a 1:2 ratio to patients in the OHCL group. RESULTS: After propensity score-matched (PSM) analysis, 61 patients remained in the LHCL group and 122 patients were in the OHCL group. What needs to be mentioned is that although not significant, patients in the OHCL group had increased lesion size (4.3 vs. 3.6 cm, p = 0.052), number (single/multiple, 84.8%/15.2% vs. 93.4%/6.6%, p = 0.097), and number of liver segments involved (one/two/three, 47.3%/42.0%/10.7% vs. 57.4%36.1%/10.7%, p = 0.393). To ensure surgical safety, fewer patients in the LHCL group underwent vascular exclusion than those in the OHCL group (p = 0.004). In addition, LHCL was associated with lower blood loss (p = 0.001) and transfusion requirement (p = 0.004). In terms of short-term outcomes, the LHCL group had significantly lower levels of peak ALT (p < 0.001), peak DBIL (p = 0.042), peak PT (p = 0.012), and higher levels of bottom ALB (p = 0.049). Moreover, the LHCL group demonstrated quicker postoperative recovery, which was represented by shorter time to first flatus, time to oral intake, time to drain off, and hospital stay (all p < 0.001). Importantly, the LHCL group had a significantly reduced occurrence of postoperative complications (p < 0.001) and similar R0 resection rates (p = 0.678) when compared to the OHCL group. CONCLUSION: LHCL is associated with increased safety and better perioperative outcomes and thus could be recommended for patients with central space-occupying liver lesions when appropriately selecting the surgical procedure according to the total tumor burden and carefully handled by experienced surgeons. From the experience of our center, LHCL could be performed to solitary lesion involving liver segment IV/V/VIII, <5 cm, with good safety and feasibility.

18.
J Immunol Res ; 2022: 2373694, 2022.
Article in English | MEDLINE | ID: mdl-35528613

ABSTRACT

Preeclampsia remains a high cause of incidence and death for mothers and fetuses in developing nations. Preeclampsia has numerous clinical and biochemical markers that have been tested, but they have failed to provide a conclusive diagnosis in the different phases of the disease's progression. Herein, our team intended to determine potential diagnostic biomarkers for preeclampsia and analyzed associations with immune cells. Two microarray data from mankind's preeclampsia and control specimens were acquired from GSE75010 and GSE44711 datasets. Differentially expressed genes (DEGs) were identified between77 normal samples and 80 preeclampsia samples. Candidate biomarkers were discovered using the least absolute shrinkage and selection operator (LASSO) and the support vector machine recursive feature elimination (SVM-RFE) analysis. The expressions and diagnostic values of genes in preeclampsia were further demonstrated in the GSE44711 dataset (8 control samples and 8 preeclampsia samples). The correlation of critical genes with the proportion of immune cells was analyzed. We identified 20 DEGs in preeclampsia. Diseases enriched by DEGs were mainly related to preeclampsia, gestational diabetes, ovarian disease, female reproductive system disease, and endocrine system disease. COL17A1, FLT1, FSTL3, and SERPINA3 were identified as diagnostic genes of preeclampsia and validated in the GSE44711 datasets. Immune cell infiltration assays suggested that COL17A1, FLT1, FSTL3, and SERPINA3 were related to several immune cells. Overall, we identified four critical diagnostic genes in preeclampsia. Furthermore, more well-designed research studies with larger cohorts were warranted to confirm the value of the four genes for the diagnosis and outcome of preeclampsia patients.


Subject(s)
Follistatin-Related Proteins , Pre-Eclampsia , Biomarkers/metabolism , Female , Humans , Pre-Eclampsia/diagnosis , Pre-Eclampsia/genetics , Pregnancy
19.
Indian J Exp Biol ; 49(8): 585-93, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21870426

ABSTRACT

Beta-arrestin 2 has been shown to participate in the pathogenesis of asthma by inducing Th2 cell migration to the lungs. Whether beta-arrestin 2 regulates cytokine production of CD4+ T cells is still unknown. The aim of the present study was to investigate the effect of beta-arrestin 2 on the cytokine production of CD4+ T lymphocytes and the mechanism involved in a mouse model for asthma. After silencing beta-arrestin 2 expression in CD4+ T lymphocytes from asthmatic mice by RNA interference (RNAi), the interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) levels in CD4+ T lymphocyte culture supernatants with or without terbutaline stimulation were determined. Cell-surface beta2 adrenergic receptor (beta2AR) as well as GATA3 expression of CD4+ T lymphocytes were also measured. CD4+ T lymphocytes of mice with allergic asthma expressed higher levels of beta-arrestin 2 on both mRNA and protein levels. beta-arrestin 2 RNAi decreased IL-4 (43.16%) and GATA3 (protein 77.21%, mRNA 62.98%) expression after terbutaline stimulation. Cell-surface beta2AR of CD4+ T lymphocytes decreased (15.27%) after terbutaline treatment, but recovered after beta-arrestin 2 RNAi down-modulation. These findings demonstrate that beta-arrestin 2 regulates IL-4 production and GATA3 expression of CD4+ T lymphocytes partly through the beta2AR signaling pathway in an allergic asthma model.


Subject(s)
Arrestins/immunology , Asthma/immunology , CD4-Positive T-Lymphocytes/immunology , Interferon-gamma/immunology , Interleukin-4/immunology , Adrenergic beta-2 Receptor Agonists/pharmacology , Animals , Arrestins/agonists , Arrestins/genetics , Blotting, Western , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/immunology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , GATA3 Transcription Factor/biosynthesis , GATA3 Transcription Factor/immunology , Interferon-gamma/biosynthesis , Interleukin-4/biosynthesis , Mice , Mice, Inbred BALB C , RNA, Small Interfering/pharmacology , Receptors, Adrenergic, beta-2/biosynthesis , Receptors, Adrenergic, beta-2/immunology , Reverse Transcriptase Polymerase Chain Reaction , Terbutaline/pharmacology , beta-Arrestin 2 , beta-Arrestins
20.
Adv Sci (Weinh) ; 8(21): e2101029, 2021 11.
Article in English | MEDLINE | ID: mdl-34486239

ABSTRACT

Recognition of specific antigens expressed in cancer cells is the initial process of cytolytic T cell-mediated cancer killing. However, this process can be affected by other non-cancerous cellular components in the tumor microenvironment. Here, it is shown that interleukin-33 (IL-33)-activated macrophages protect melanoma cells from tumor-infiltrating lymphocyte-mediated killing. Mechanistically, IL-33 markedly upregulates metalloprotease 9 (MMP-9) expression in macrophages, which acts as a sheddase to trim NKG2D, an activating receptor expressed on the surface of natural killer (NK) cells, CD8+ T cells, subsets of CD4+ T cells, iNKT cells, and γδ T cells. Further, MMP-9 also cleaves the MHC class I molecule, cell surface antigen-presenting complex molecules, expressed in melanoma cells. Consequently, IL-33-induced macrophage MMP-9 robustly mitigates the tumor killing-effect by T cells. Genetic and pharmacological loss-of-function of MMP-9 sheddase restore T cell-mediated cancer killing. Together, these data provide compelling in vitro and in vivo evidence showing novel mechanisms underlying the IL-33-macrophage-MMP-9 axis-mediated immune tolerance against cancer cells. Targeting each of these signaling components, including IL-33 and MMP-9 provides a new therapeutic paradigm for improving anticancer efficacy by immune therapy.


Subject(s)
Immunity/drug effects , Interleukin-33/pharmacology , Lymphocytes, Tumor-Infiltrating/immunology , Macrophages/immunology , Animals , Disease Models, Animal , Histocompatibility Antigens Class I/metabolism , Humans , Killer Cells, Natural/cytology , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/metabolism , Lymphocytes, Tumor-Infiltrating/cytology , Lymphocytes, Tumor-Infiltrating/metabolism , Macrophages/cytology , Macrophages/drug effects , Macrophages/metabolism , Matrix Metalloproteinase 9/chemistry , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Melanoma/immunology , Melanoma/therapy , Mice , NK Cell Lectin-Like Receptor Subfamily K/metabolism , Neoplasms/immunology , Neoplasms/therapy , RNA Interference , RNA, Small Interfering/metabolism , Up-Regulation/drug effects , Zebrafish
SELECTION OF CITATIONS
SEARCH DETAIL